Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
Last updated on July 2021Recruitment
- Recruitment Status
- Terminated
- Estimated Enrollment
- 3
Summary
- Conditions
- Juvenile Idiopathic Arthritis
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 2 years and 18 years
- Gender
- Both males and females
Description
Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF?, which are involved in the pathogenesis of the arthritic process.
Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF?, which are involved in the pathogenesis of the arthritic process.
Tracking Information
- NCT #
- NCT01557452
- Collaborators
- Parexel
- Investigators
- Principal Investigator: Pavla Dolezalova, MD General Faculty Hospital Department of Pediatrics and Adolescent Medicine, Praha, Czech Republic
Get Well Soon